Success Story: Overcoming RFE for an EB-1A Approval for a Biomedical Engineering Researcher Advancing Gene and Drug Delivery Technologies
Client’s Testimonial:
"Again, thanks for helping through the process, so happy it worked out.”
On June 29th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Researcher in the Field of Biomedical Engineering (Approval Notice).
General Field: Biomedical Engineering
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: China
State of Residence at the Time of Filing: North Carolina
Approval Notice Date: June 29th, 2026
Processing Time: 22 months, 6 days (Premium Processing Upgrade Requested)
Case Summary:
We are pleased to share that the client’s I-140 EB-1A petition was approved after receiving a Request for Evidence (RFE). The client is a biomedical engineering researcher specializing in drug delivery, gene delivery, vaccine delivery, gene therapy, and immunotherapy, with an M.S.E. in biomedical engineering and a B.S. in pharmacy. At the time of filing, the client was conducting research at a U.S. institution, focusing on nanoparticle-based therapeutic systems and scalable delivery methods for mRNA and viral vectors.
Research Focus
The client’s proposed endeavor focused on advancing therapeutic delivery technologies and improving treatment strategies in biomedical engineering. His work involves developing innovative approaches to enhance the effectiveness and scalability of emerging therapies, including gene-based and immunological treatments. These efforts contribute to improving the safety, efficiency, and accessibility of advanced medical interventions.
Evidence of Professional Record
The client’s publication record included 20 peer-reviewed journal articles (3 first-authored, 2 co-first-authored) and 1 preprint article, with 634 citations. He has conducted at least 10 peer reviews for high-impact journals. Funding support has been provided by the National Institutes of Health, the National Institute of Biomedical Imaging and Bioengineering, and Bluebird Bio, Inc.
How We Demonstrated Significance
We demonstrated the client’s significance by showing that his work has been widely cited and used by researchers worldwide in studies advancing tumor therapies, mRNA vaccine formulations, and scalable nanoparticle production. Independent researchers have applied his methodologies to develop improved therapeutic delivery systems, demonstrating that his contributions have practical and scientific value across biomedical engineering.
Why the Case Met the EB-1A Standard
The petition demonstrated that the client meets the EB-1A criteria for extraordinary ability by showing sustained national and international acclaim, original contributions of major significance, and influence in the field of biomedical engineering. The client’s record of high-impact publications, extensive citations, peer-review activity, and funded research confirmed that he is among the top researchers in his field. His work addresses critical national priorities in gene therapy, immunotherapy, and biopharmaceutical development, and his continued research in the U.S. is expected to substantially benefit the nation.
Recommendation Letters
The case was supported by 6 recommendation letters from experts in biomedical engineering and gene/drug delivery. The letters highlighted the client’s innovative contributions to mRNA and viral vector delivery systems, the originality of his research, and the broad scientific impact of his work. One expert noted:
“[Client] is a highly successful and influential researcher, and there is no doubt that he will continue to revolutionize the field of biomedical engineering.”
Approval
The I-140 EB-1A petition was filed on August 23rd, 2024, later upgraded to Premium Processing, and approved on June 29th, 2026, after an RFE. This approval reflects the client’s outstanding scientific contributions, recognition by peers, and the national importance of his research in advancing biomedical engineering and therapeutic delivery systems.
We congratulate the client on this EB-1A approval and look forward to his continued contributions to biomedical engineering, gene therapy, and drug delivery technologies in the United States.